Throughout the last three months, 4 analysts have evaluated Surgery Partners (NASDAQ:SGRY), offering a diverse set of opinions from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $44.25, a high estimate of $49.00, and a low estimate of $42.00. This upward trend is apparent, with the current average reflecting a 2.91% increase from the previous average price target of $43.00.

Decoding Analyst Ratings: A Detailed Look

The standing of Surgery Partners among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into Surgery Partners's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Surgery Partners analyst ratings.

Delving into Surgery Partners's Background

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.

Surgery Partners: A Financial Overview

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Surgery Partners displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 4.0%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Surgery Partners's net margin is impressive, surpassing industry averages. With a net margin of -0.14%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Surgery Partners's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.05%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Surgery Partners's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.01%, the company showcases efficient use of assets and strong financial health.

Debt Management: Surgery Partners's debt-to-equity ratio is below the industry average. With a ratio of 1.54, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Understanding the Relevance of Analyst Ratings

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.